RhumbLine Advisers
GBIO

RhumbLine Advisers’s Generation Bio GBIO Stock Holding History

RhumbLine Advisers’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,975
Closed -$28.2K – 4185
2025
Q1 		$28.2K Sell
6,975
-370
-5% -$2.6K ﹤0.01% 3683
2024
Q4 		$77.8K Sell
7,345
-217
-3% -$3.87K ﹤0.01% 3547
2024
Q3 		$187K Sell
7,562
-328
-4% -$8.68K ﹤0.01% 3271
2024
Q2 		$222K Buy
7,890
+543
+7% +$17.6K ﹤0.01% 3167
2024
Q1 		$299K Buy
7,347
+160
+2% +$3.77K ﹤0.01% 2980
2023
Q4 		$119K Buy
7,187
+49
+0.7% +$854 ﹤0.01% 3396
2023
Q3 		$271K Sell
7,138
-5
-0.1% -$237 ﹤0.01% 2982
2023
Q2 		$393K Sell
7,143
-348
-5% -$16K ﹤0.01% 2844
2023
Q1 		$322K Buy
7,491
+58
+0.8% +$2.81K ﹤0.01% 2591
2022
Q4 		$292K Buy
7,433
+367
+5% +$19.3K ﹤0.01% 2686
2022
Q3 		$375K Buy
7,066
+588
+9% +$36.8K ﹤0.01% 2627
2022
Q2 		$425K Buy
6,478
+2,062
+47% +$135K ﹤0.01% 2580
2022
Q1 		$324K Buy
4,416
+28
+0.6% +$1.62K ﹤0.01% 2617
2021
Q4 		$311K Sell
4,388
-123
-3% -$21.5K ﹤0.01% 2689
2021
Q3 		$1.13M Buy
4,511
+197
+5% +$47.2K ﹤0.01% 2166
2021
Q2 		$1.16M Buy
4,314
+94
+2% +$28.1K ﹤0.01% 2178
2021
Q1 		$1.2M Buy
4,220
+2,850
+208% +$912K ﹤0.01% 2124
2020
Q4 		$388K Buy
1,370
+247
+22% +$79.3K ﹤0.01% 2549
2020
Q3 		$347K Buy
+1,123
New +$269K ﹤0.01% 2453

Other funds holding GBIO

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RhumbLine Advisers's GBIO Position: Q2 2025 in Review

RhumbLine Advisers sold out of Generation Bio (GBIO) in Q2 2025, closing a stake of 6,975 shares — an estimated $28.2K sold.

RhumbLine Advisers first reported a position in GBIO in Q3 2020 and held it in 19 quarters. The position peaked at $1.2M in Q1 2021. 61 funds tracked by Wall St. Rank hold GBIO as of Q2 2025.

  • RhumbLine Advisers reported no remaining Generation Bio position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 6,975 Generation Bio shares in Q2 2025, an estimated $28.2K.
  • RhumbLine Advisers first reported a position in Generation Bio in Q3 2020 and held it in 19 quarters.
  • RhumbLine Advisers's Generation Bio position peaked at $1.2M in Q1 2021.
  • 61 funds tracked by Wall St. Rank held Generation Bio as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.